All In Biotech

NDA 020330 · Bausch and Lomb INC

Timoptic-Xe

Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jul 16, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Nov 4, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

7,816

3,745 serious, 443 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2025.

INDICATIONS AND USAGE Timolol Maleate Sterile Ophthalmic Gel Forming Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Mechanism: Mechanism of Action Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Timolol Maleate Ophthalmic Gel Forming Solution, when applied topically on the eye, has the action of reducing elevated, as well as normal intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. The precise...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 4, 1993 Original approval · Type 3 - New Dosage Form
2 products under this application
  • TIMOPTIC-XE · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB
  • TIMOPTIC-XE · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION, GEL FORMING/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure979
  • drug ineffective575
  • eye pain445
  • fatigue413
  • eye irritation362
  • dizziness296
  • diarrhoea285
  • nausea264
  • vision blurred264
  • off label use261
  • headache244
  • ocular hyperaemia235

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004170
2005203
2006164
2007151
2008143
2009140
2010212
2011229
2012313
2013113
2014147
2015245
2016287
2017337
2018351
2019395
20201,433
2021408
2022439
2023513
2024519
2025558
2026345

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,308 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.